A "Power Duo" in the Field of Diabetes Management

According to Siyu MedTech, medical device giants Abbott and Medtronic have recently announced a collaboration in the field of diabetes management. The partnership will combine Abbott’s continuous glucose monitoring (CGM) technology with Medtronic’s insulin delivery systems. Abbott will be responsible for sensor development, while Medtronic will handle market promotion. The companies have not disclosed specific financial details.

The core of this collaboration is the integration of Abbott’s FreeStyle Libre 3 CGM with Medtronic’s MiniMed 780G automated insulin pump and InPen smart insulin pen. The goal is to develop a comprehensive diabetes management system. This system will use Abbott’s CGM’s high-precision monitoring alongside Medtronic’s intelligent algorithms to automatically adjust insulin delivery, helping to maintain stable blood glucose levels for patients.

FreeStyle Libre 3, as the next-generation CGM, has been significantly reduced in size and offers a 14-day battery life. It also includes high and low blood sugar alerts. With Bluetooth connectivity, patients can view their blood sugar data in real-time through a mobile app. It is suitable for patients aged 4 years and older.

Additionally, Abbott has partnered with other insulin pump manufacturers, such as Tandem’s t:slim X2 pump and Insulet’s Omnipod 5, further expanding Libre’s compatibility and offering more options for patients.